Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
interferon alfa-2c
- Development stage
- Preclinical
- Lead developer
- Boehringer Ingelheim
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Intramuscular, Intravenous, Intralesional
01
Overview
Interferon alfa-2c is a recombinant type I interferon, specifically an alpha subtype, used as an immunomodulatory and antiviral agent. Like other type I interferons, it exerts its effects by binding to the type I interferon receptor (IFNAR), which consists of IFNAR1 and IFNAR2 subunits expressed on most cell types. Upon receptor engagement, it activates the JAK-STAT signaling pathway—specifically Janus kinases (JAK1 and TYK2)—leading to phosphorylation of STAT1 and STAT2 transcription factors. These form a complex with IRF9 called ISGF3 that translocates to the nucleus to induce expression of hundreds of interferon-stimulated genes (ISGs). The resulting proteins inhibit viral replication, enhance immune surveillance against tumors, and modulate cellular proliferation[6]. Interferon alfa-2c has been investigated for use in various viral infections (such as hepatitis B and C) and certain cancers[1].
- Brand names
- Berofor
- Other names
- recombinant interferon alpha-2cIFN-α2c
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)
Beyond the preview
Go deeper on interferon alfa-2c.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on interferon alfa-2c.